Ropinirole - Antares Pharma/Jazz Pharmaceuticals

Drug Profile

Ropinirole - Antares Pharma/Jazz Pharmaceuticals

Alternative Names: AP-1126; JZP-7; Ropinirole ATD™ Gel; Ropinirole transdermal gel

Latest Information Update: 16 Aug 2010

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Antares Pharma
  • Developer Jazz Pharmaceuticals
  • Class Amines; Antiparkinsonians; Indoles; Sleep disorder therapies; Small molecules
  • Mechanism of Action Dopamine D2 receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • Discontinued Restless legs syndrome

Most Recent Events

  • 10 Aug 2010 Discontinued - Phase-I for Restless legs syndrome in USA (Transdermal)
  • 15 Apr 2008 Jazz Pharmaceuticals completes a second phase I, pharmacokinetic trial for Restless legs syndrome in USA
  • 13 Mar 2008 Jazz Pharmaceuticals has completed a phase I, pharmacokinetic trial for Restless legs syndrome in USA
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top